(Q50541159)

15 March 2018

title

Radiofrequency ablation as first-line treatment for small solitary hepatocellular carcinoma: Long-term results (English)

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

14 July 2024

main subject

hepatocellular carcinoma

1 reference

2

Y-J Zhang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846819

14 July 2024

author name string

Z-W Peng

1

1 reference

15 March 2018

M-S Chen

3

1 reference

15 March 2018

X-J Lin

4

1 reference

15 March 2018

H-H Liang

5

1 reference

15 March 2018

M. Shi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846819

14 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20846819

14 July 2024

publication date

16 September 2010

1 reference

15 March 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S0748798310004750?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

https://api.elsevier.com/content/article/PII:S0748798310004750?httpAccept=text/plain

14 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

European Journal of Surgical Oncology

14 July 2024

published in

1 reference

15 March 2018

volume

36

1 reference

15 March 2018

issue

11

1 reference

15 March 2018

page(s)

1054-1060

1 reference

15 March 2018

Management of hepatocellular carcinoma

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Are increasing 5-year survival rates evidence of success against cancer?

14 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).

14 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list

14 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Liver transplantation for hepatocellular carcinoma

14 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

14 July 2024

Hepatocellular carcinoma

6

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Hepatic resection for hepatocellular carcinoma. An audit of 343 patients

14 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.

14 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis

14 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

14 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma

14 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review.

14 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

14 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients--mathematic model, overlapping mode, and electrode placement process.

14 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Percutaneous radiofrequency ablation for the treatment of hepatocellular carcinoma in the caudate lobe

14 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Radiofrequency ablation of hepatocellular carcinoma with a saline solution perfusion device: a pilot study.

14 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

14 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma

14 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis?

14 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors

14 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study

14 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence

14 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas

14 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC).

14 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial

14 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.

14 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series

14 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases

14 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma

14 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.EJSO.2010.08.133

14 July 2024

Identifiers

1 reference

15 March 2018

1 reference

15 March 2018